Pipeline

MolMed is developing two novel investigational treatments, prototypes of new therapeutic classes, resulting from two different technological approaches:

• TK, a cell therapy product for the treatment of haematological malignancies, which provides for the treatment of patients undergoing haplo-identical bone marrow transplantation with cells genetically modified ex vivo to express a gene allowing prompt control and abrogation of the possible onset of Graft versus Host Disease (GvHD) reaction

• NGR-hTNF, a recombinant biological drug for the treatment of solid tumours, which displays antitumour activity through its specific binding to blood vessels feeding the tumour mass.